Effect of Oral Propranolol on Periocular Infantile Capillary Hemangioma: Outcomes Based on Extent of Involvement.
Capillary hemangioma
eye
eyelid
propranolol
tumor
Journal
Middle East African journal of ophthalmology
ISSN: 0975-1599
Titre abrégé: Middle East Afr J Ophthalmol
Pays: India
ID NLM: 101521797
Informations de publication
Date de publication:
Historique:
received:
09
09
2019
revised:
29
12
2020
accepted:
03
02
2021
entrez:
29
7
2021
pubmed:
30
7
2021
medline:
6
10
2021
Statut:
epublish
Résumé
To evaluate the efficacy of oral propranolol in the treatment of periocular infantile capillary hemangioma (CHI) based on the involvement of embryological facial placodes and their extent of anatomical involvement. Retrospective study of 27 patients. The mean age at the presentation of periocular CHI was 4 months (median, 3 months; range, <1-14 months). There were 11 (41%) males and 16 (59%) females. Based on embryological facial placodes, the involvement was focal in 16 (59%) cases and segmental in 11 (41%) cases. Based on the anatomical distribution, the lesions were preseptal in 4 (15%), postseptal in 13 (48%), and combined in 10 (37%) cases. The duration of use of oral propranolol was 10 months (median, 10 months; range, 4-16 months). Overall, the mean % resolution of periocular CHI was 78% (median, 90%; range, 20%-100%). The mean percentage resolution of focal lesions was 69% (median, 83%; range, 20%-100%), and segmental lesions were 92% (median, 95%; range, 70%-100%). The mean percentage resolution of preseptal component of lesions was 94% (median, 95%; range, 80%-100%) and postseptal component was 74% (median, 85%; range, 20%-100%) over a mean follow-up period of 16 months (median, 15 months; range, 4-37 months). Four (15%) patients exhibited flare-up of lesion after tapering oral propranolol. Oral propranolol is effective in the treatment of periocular CHI. Segmental and preseptal lesions respond better to the treatment compared to focal and postseptal lesions.
Identifiants
pubmed: 34321816
doi: 10.4103/meajo.MEAJO_228_19
pii: MEAJO-28-6
pmc: PMC8270022
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-10Informations de copyright
Copyright: © 2021 Middle East African Journal of Ophthalmology.
Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Eye (Lond). 2011 Dec;25(12):1627-34
pubmed: 21921959
Pediatrics. 2015 Oct;136(4):786-91
pubmed: 26416928
N Engl J Med. 2008 Jun 12;358(24):2649-51
pubmed: 18550886
Pediatr Dermatol. 2004 Jan-Feb;21(1):1-9
pubmed: 14871317
Arch Dermatol. 2001 May;137(5):559-70
pubmed: 11346333
AJR Am J Roentgenol. 1998 Jul;171(1):247-52
pubmed: 9648798
Am J Ophthalmol. 1977 Jan;83(1):52-8
pubmed: 835667
Dev Biol. 2006 Jun 15;294(2):303-51
pubmed: 16677629
Am J Ophthalmol. 2004 Jun;137(6):1065-72
pubmed: 15183791
Pediatr Neonatol. 2018 Aug;59(4):390-396
pubmed: 29301720
Eye (Lond). 2011 Oct;25(10):1277-83
pubmed: 21738233
Acta Ophthalmol. 2012 Dec;90(8):727-32
pubmed: 21457487
J Pediatr. 2010 Dec;157(6):881-8.e1-5
pubmed: 20884010
Br J Ophthalmol. 2012 Mar;96(3):370-4
pubmed: 21673014
Am J Ophthalmol. 1978 Jun;85(6):806-13
pubmed: 677206
Arch Dermatol. 2003 Jul;139(7):869-75
pubmed: 12873881
J AAPOS. 2006 Jun;10(3):262-8
pubmed: 16814181
Pediatrics. 2009 Sep;124(3):e423-31
pubmed: 19706583
Hum Pathol. 2000 Jan;31(1):11-22
pubmed: 10665907
Surv Ophthalmol. 1994 Mar-Apr;38(5):399-426
pubmed: 8009426